Original Research

Stimulant Medication Prescribing Practices Within a VA Health Care System

Author and Disclosure Information

 

References

Conclusion

Our data show that there is still substantial room for improvement in the prescribing and monitoring of stimulant medications. The rate of stimulant prescribing inconsistency, prescriber-hopping, and unsupported ADHD diagnosis resulting from formal diagnostic testing warrant a review in the processes for transition of care regarding stimulant medications, both within and outside of this facility. A lack of consistent monitoring was also identified in this study. One of the most appreciable areas of opportunity resulting from this study is the need for consistency in both the prescribing and monitoring of stimulant medications. From the above results investigators concluded that this facility may benefit from implementation of a CPP for stimulant prescribing as well as a chronic stimulant management agreement to provide clear expectations for patients and prescribers prior to and during prescription stimulant use.

Acknowledgments

We thank Tori Wilhoit, PharmD candidate, and Dana Fischer, PharmD candidate, for their participation in data collection and Courtney Eatmon, PharmD, BCPP, for her general administrative support throughout this study.

Pages

Recommended Reading

A triple-antibiotic cure for Crohn’s disease?
Federal Practitioner
Experts call to revise the Uniform Determination of Death Act
Federal Practitioner
CAR T-cell therapy may worsen mental health in some patients
Federal Practitioner
ATLAS Opens New Telehealth Site With Walmart
Federal Practitioner
Washington state patient is first U.S. case of novel coronavirus
Federal Practitioner
Carbs, fat, and mortality: Types matter more than levels
Federal Practitioner
GAO Finds DoD Can Do More to Recruit and Retain Physicians and Dentists
Federal Practitioner
Wuhan virus: What clinicians need to know
Federal Practitioner
Opioid deaths boost donor heart supply
Federal Practitioner
HHS: Coronavirus risk low in U.S., vaccine development underway
Federal Practitioner